Neothetics (NEOT) Given Media Sentiment Rating of 0.18
News headlines about Neothetics (NASDAQ:NEOT) have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Neothetics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.344990724835 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Neothetics (NASDAQ:NEOT) opened at $1.67 on Thursday. Neothetics has a 12 month low of $0.30 and a 12 month high of $2.63.
Neothetics (NASDAQ:NEOT) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter.
Separately, ValuEngine raised shares of Neothetics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, October 17th.
COPYRIGHT VIOLATION NOTICE: This story was first published by Daily Political and is owned by of Daily Political. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/12/21/neothetics-neot-given-media-sentiment-rating-of-0-18.html.
Neothetics, Inc is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
Receive News & Ratings for Neothetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neothetics and related companies with MarketBeat.com's FREE daily email newsletter.